Biotechnology Just days after agreeing acquisition terms with takeover suitor Sanofi-Aventis (Euronext: SAN; The Pharma Letter February 16), US biotech firm Genzyme (Nasdaq: GENZ) announced three-year follow-up data from patients enrolled in the Phase II clinical trial for its investigational oral therapy for Gaucher disease type 1, eliglustat tartrate, raising hope for a second treatment to add to its rare disease portfolio, which already includes Cerezyme (imiglucerase for injection) for Gaucher and Fabry disease agent Fabrazyme (agalsidase beta). 21 February 2011